Reports say PAHO revoked U.S. measles elimination status; school accommodations fail in ADHD trial; Alaris kit correction made Class I

Listen to this post
read by AI voices · all episodesThe Pan American Health Organization has revoked U.S. measles elimination status, according to a Wall Street Journal report cited by Reuters on Nov. 13, as 2026 U.S. cases reached 5,412.
A JAMA Pediatrics trial found academic accommodations did not help children with ADHD, the Food and Drug Administration classed a correction of kits with BD Alaris infusion sets, an issue that puts neonates at highest risk, as its most serious recall type and a meta-analysis favored habitus-corrected length tapes for resuscitation dosing.
- Public health Nov 13, 2026The Pan American Health Organization (PAHO) has revoked the measles elimination status of the United States, according to a Wall Street Journal report cited by Reuters on Nov. 13, Contagion Live reported; PAHO did not immediately respond to a request for comment on the report. Reuters had reported Nov. 11 that the determination was expected to be made public early the following week. The Centers for Disease Control and Prevention (CDC) reported 5,412 confirmed cases in 2026 as of Nov. 12; its website lists six deaths, while state health departments have reported 10, according to Contagion Live.
- Research Nov 13, 2026In a crossover randomized trial in summer treatment program classrooms, published Nov. 13 in JAMA Pediatrics, no academic accommodation significantly improved behavior or academic outcomes among 255 children in kindergarten through sixth grade with ADHD. Stimulant medication raised seatwork productivity (rate ratio 1.22, 95% CI 1.19 to 1.25) and quiz scores by 3.9 points, and classroom rule-breaking fell 37% with medication and 61% with behavioral therapy. The authors wrote that the results question continued emphasis on school-based accommodations.Sources: JAMA Pediatrics, PubMed
- FDA Nov 9, 2026The Food and Drug Administration (FDA) on Nov. 9 classified Cardinal Health's correction of Presource kits containing BD Alaris Pump infusion sets, an update to use instructions, as a Class I recall, its most serious type, updating an Oct. 20 early alert. Set performance deviations, most often at rates under 1 mL/h and bolus volumes of 5 mL or less, can cause under- or over-infusion, with neonates, children and critically ill patients at highest risk. FDA lists an alternative syringe pump among options; BD reported no serious injuries or deaths as of Aug. 19.Source: FDA
- Research Nov 10, 2026A systematic review and meta-analysis of 250 studies, published Nov. 10 in Pediatrics, found the PAWPER tape, a length-based tape with habitus correction, superior to the Broselow tape for time to drug administration, dose accuracy and weight estimation accuracy, with an odds ratio of 2.48 (95% CI 2.04 to 3.02) for estimates within 10%. All age-based formulas were consistently inaccurate. Only nine studies enrolled children requiring resuscitation, and there were no patient outcome data.Sources: Pediatrics, PubMed
The weekly innovation roundup for pediatrics, published every Sunday for the week before; every item links to its sources. Latest pediatrics news · All specialties